Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests Feb 22, 2022
Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests Jan 28, 2022
Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering Jan 12, 2022
Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering Jan 3, 2022
Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans Nov 2, 2021
Interpace Biosciences Announces U.S. PTO Issuance of Patent No. 11,143,657 Titled: Topographic Genotyping for Determining the Diagnosis, Malignant Potential, and Biologic Behavior of Pancreatic Cysts and Related Conditions Oct 28, 2021
Interpace Diagnostics Announces US Patent Approval for Patent Application No. 11,118, 231 B2 Titled: microRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms Oct 21, 2021
